The bidding window for Monolithisch India SME IPO was open from June 12, 2025, to June 16, 2025. The basis of allotment will be finalised today, June 17, 2025. If you have applied for the IPO, here’s how you can check the allotment status on the NSE and the registrar’s website.
Monolithisch India IPO is a book-building issue of ₹82.02 crores, consisting entirely of a fresh issue of 54.48 lakh equity shares. The price band is set at ₹143 per share. The tentative listing on NSE Emerge is June 19, 2025.
Hem Securities Limited is the book-running lead manager, and Kfin Technologies is the registrar for the issue.
The net proceeds from the fresh issue will be used towards:
(June 16, 2025, end of the day)
Category |
Subscription (times) |
Qualified Institutional Investors (QIBs) |
129.20 |
Non-Institutional Investors |
459.99 |
Retail Individual Investors(RIIs) |
94.71 |
Total |
182.89 |
Monolithisch India IPO GMP Details
As of 17 June 2025, Monolithisch India IPO GMP stood at ₹43. The expected listing price is ₹186, i.e., a 30.07% gain per share over the upper price band.
Source: Business Standard Report dated 17 June, 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market. |
Monolithisch India manufactures and supplies ramming mass, a refractory consumable used primarily in Induction Furnaces within iron, steel, and foundry plants. Over the years, the company has developed a wide range of customised grades and formulations of ramming mass to cater to the diverse technical specifications required by furnaces of varying capacities and designs.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here